Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Post-Test/Evaluation

Exit Survey

Questions marked with a * are required

25%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Which of the following statements is true regarding EGFR mutations in NSCLC?

Liquid biopsy can exclude an EGFR mutation in metastatic NSCLC

PCR-based testing is preferred over next generation sequencing for a faster turnaround

Most EGFR mutations are an exon 18 or 20 deletion

The majority of EGFR mutations are an exon 19 deletion or an L858R point mutation in exon 21.

What is true regarding the clinicopathologic features of EGFR-mutations in patients with NSCLC?

Ethnicity, smoking status, and histology should be used to select patients for testing of EGFR mutations

EGFR mutations generally occur in young males of Hispanic descent

Patients with the exon 19 mutation have a better prognosis than those with an L858R point mutation

A large meta-analysis found that patients with the exon 20 deletion responded better to treatment with EGFR-tyrosine kinase inhibitors than patients with the exon 19 mutation

A 61-year-old man is diagnosed with stage IV NSCLC with EGFR exon 21 (L858R) mutation. He has no CNS metastases and his Eastern Cooperative Oncology Group (ECOG) performance status (PS) is 1. Which one of the following VEGF-targeted treatments is FDA-approved for use in combination with erlotinib for first-line management?

Dacomitinib

Gefitinib

Pembrolizumab

Ramucirumab

Your patient is a 67-year-old woman with EGFR exon 20 insertion mutation-positive metastatic NSCLC that doesn’t respond to first-line chemotherapy. His ECOG PS is 1. Based on patient-specific factors, what would be the next best treatment option for this patient?

Amivantamab

Docetaxel

Erlotinib

Pembrolizumab